A disease-education material explains an illness: what symptoms appear, what mechanism drives it, and how to live with it. On its face it is not a product advertisement but an aid to understanding the disease itself. In practice, though, because a pharmaceutical company produces it, the company's own product always sits somewhere behind the page. That is precisely why the creation guide treats this material as its own chapter and holds it to rules distinct from ordinary promotional pieces.
The starting point is classification. Even within "disease education," the permitted range of expression changes completely depending on who receives the material and why. The guide divides it, by audience and purpose, into patient-facing disease-education materials and healthcare-professional-facing disease-education materials. Whether the reader is an ordinary patient or a specialist who holds prescribing authority is the premise on which every later judgment rests.
Classification comes first for a simple reason: depending on the reader, the very same sentence can be either a helpful explanation or an unlawful advertisement. The design philosophy starts from the reader's medical literacy and from how the information might move prescribing or care-seeking behavior.
02The Frame Patient-Facing Materials Must Hold
Patient-facing materials sit under the Pharmaceuticals and Medical Devices Act, the fair advertising standards, and related rules. The content must be necessary and appropriate for a lay reader, that is, a patient without medical training. This premise of a lay reader imposes tight constraints, because errors a specialist would correct from context may be taken at face value by a patient.
At the core lies one line that must not be crossed: the material must not be read as the advertisement of a specific drug. If, under the guise of disease education, it effectively steers patients toward the company's own product, it is nothing more than evasive promotion slipping past the ban on advertising prescription drugs to patients. The guide builds up concrete sub-rules to keep this line intact.
Keep the Explanation of the Disease at the Center
A patient-facing material is built around explaining the illness. Even when it touches on treatment, it should present the commonly assumed options fairly and not lean toward any specific drug. Drawing one option large and the others small lets the layout itself argue "choose this drug." Fair presentation means neutrality reaching down to layout, length, and tone.
No Clinical Results; Stop at the Therapeutic-Class Name
Patient-facing materials carry no clinical results for treatment drugs. Response rates and figures are information whose interpretation requires specialist premises, and a patient cannot weight them correctly alone. When a drug must be mentioned, the material stops at the therapeutic-class name. By withholding the specific product name, it physically preserves the boundary between "explaining the disease" and "recommending a product."
There is a "same data, different reader" trap. Clinical figures that a healthcare professional would interpret soundly can, the moment they are placed in a patient-facing piece, breed inflated hope or false reassurance. Fitness is decided not only by whether the information is correct, but by who receives it. Lose this sense and a well-meant explanation becomes a seedbed for misunderstanding.
Leave a Bridge to Seeing a Doctor
Patient-facing materials prompt consultation with a physician where appropriate. Rather than letting the material stand alone, leaving room to connect to a specialist's judgment bears directly on patient safety. When a self-check or similar self-assessment tool is included, it must not give the impression that the presence or absence of symptoms settles the diagnosis. A check is only a trigger; confirming a diagnosis is the physician's role, and the material itself must state this line.
The Discipline of Avoiding Misunderstanding
An explanation of risk, even if medically correct, can depending on its wording invite the misreading that "if it applies to you, you will certainly develop the disease." Care is needed so that probabilities and risk factors are not reread as deterministic certainties. The opposite misreading is equally forbidden: do not give the impression that one will certainly be cured. Speaking of hope is not the same as promising a cure. Nor should symptoms alone be made to seem to settle the disease. Each of these gives concrete patient-facing form to the foreword's spirit of avoiding not only falsehood but also misunderstanding.
Issue
Impression to avoid
Stance required
Self-check
Symptoms mean the disease is confirmed
A trigger to seek care; diagnosis is the physician's
Risk explanation
If it applies, onset is certain
Correct, yet not read as deterministic
Treatment outlook
Certain cure
Do not create excessive expectation
Handling of drugs
Steering toward a specific product
Therapeutic-class name only; fair
Naming the Company
Patient-facing materials state the name of the company that produced them. Making clear who issued the information is a premise for the reader to gauge the nature of that information. Disease education that hides its source is itself wanting in honesty.
03The Different Discipline for Professional-Facing Materials
When the reader is a healthcare professional, the range of information that may be carried widens. But this does not mean "anything goes"; it is a conditional widening, on the terms that if you carry it, you must follow the matching framework.
If concrete clinical results are to be included, the material is prepared as a specific-item product information summary. The product information summary is a fixed vessel for presenting evidence without excess or deficiency and without steering; once results are spoken of, they are made to obey its discipline. Even when stopping at the therapeutic-class name, if reference information is added, it is arranged in the spirit of a specific-item summary. And as with patient-facing materials, the company name is stated.
Under the same name "disease education," the vessel differs between patient-facing and professional-facing. The former severs its advertising character by suppressing product names and results; the latter may carry results but only inside the frame of a product information summary. Freedom of information and the framework that governs it are traded off against each other. This exchange is the essence of the two-way classification.
04Why Divide So Finely
Each sub-rule looks fussy, yet the root is single. Treat the electronic package insert as the original, complement it, and avoid both falsehood and misunderstanding. The provisions of this chapter are that foreword spirit made concrete according to differences in the reader.
A patient can hardly measure the weight of figures alone, and a slight tilt in wording moves decisions about care-seeking and medication. So strong information such as product names and clinical results is suppressed, while fairness of explanation and a bridge to consultation are preserved. A healthcare professional can interpret figures, but precisely because they can, the presentation is placed on the discipline of the product information summary to prevent arbitrary cropping. Even areas the Act does not address in explicit text are governed by higher norms such as the fair advertising standards and the code. The foreword's posture of filling unwritten ground with higher norms is alive here too.
In closing
A disease-education material first splits by reader. The patient-facing kind, so as not to be read as the advertisement of a specific product, keeps the explanation central, presents options fairly, carries no clinical results, and stops at the therapeutic-class name for drugs. In self-checks and risk explanations it avoids any impression of a confirmed diagnosis or of certain onset or certain cure, and it never omits the bridge to physician consultation or the company name.
The professional-facing kind, if it carries concrete results, is made as a specific-item product information summary; if it adds reference information, it is arranged in the spirit of a specific-item summary; and it likewise names the company. Freedom of information is traded against framework. Every sub-rule flows from one spirit: avoid not only falsehood but also misunderstanding.
Case studies — the "it isn't written, so…" mindset, and how each lands
Disease-education materials present themselves as neutral patient information — a framing that makes it easy to disguise product steering as thoroughness. The two-tier structure (patient-facing vs. healthcare professional-facing) also creates apparent gaps: "neither ruleset says anything about this specific situation." Four scenarios and verdicts follow.
GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)
The scheme: "When listing treatment options in a patient-facing material, I'll give two paragraphs of detailed explanation to the pharmacological class that contains our product, while covering every other option in one or two sentences. No product name appears, and I'm using only the pharmacological class name as required."
Verdict: GRAY 1. "Presenting options fairly" includes layout, word count, and tone — not just the absence of a product name. Devoting two paragraphs to one class and one sentence to all alternatives creates a gravitational pull toward the well-explained option without saying a single product name. The rule against directing the patient's attention toward a specific drug is violated by design, even if no individual drug is named. Fairness does not require identical word counts, but any structural disparity large enough to skew the reader's attention falls outside the spirit of the provision.
GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)
The scheme: "At the bottom of a self-assessment checklist in patient materials, I'll add: 'If you checked three or more items, ask your doctor about [pharmacological class name] ([target] inhibitors).' No product name — just the class name — so the pharmacological-class-name-only rule is followed. It is simply an appropriate referral bridge."
Verdict: GRAY 2. The class-name-only rule is about not naming a specific product. It does not authorise linking a self-assessment result directly to a specific pharmacological class as if it were a prescribing recommendation. Telling patients who score above a threshold to ask specifically about one class of drug channels them toward the products in that class — which in practice means the company's own products. The permitted referral bridge in patient materials is a general prompt to consult a physician. Tying a symptom-count threshold to a named drug class converts the self-assessment into a targeted steering tool, functioning as a product advertisement under a different label.
GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)
The scheme: "I'll insert one boxed sentence in the patient material: 'In a clinical trial, [X]% of patients showed improvement at Week 12.' I'll label it 'for reference,' not name the product, and use only the pharmacological class. It gives patients useful context."
Verdict: GRAY 3. The rules for patient-facing materials explicitly state that clinical trial results must not be included. "For reference" labelling does not exempt the content from that prohibition. A response rate figure requires understanding of individual variability, trial conditions, the comparator, and statistical assumptions to be interpreted correctly — competencies that patients without medical training cannot be assumed to have. An "[X]% improved" figure read without that context creates over-optimistic expectations. The PMD Act and Fair Advertising Standards treat clinical efficacy data in patient materials as inherently misleading to a lay audience, regardless of how the data is framed.
BLACK — Breaching the explicit text (a plain violation of the provision itself)
The scheme: "The patient-facing disease education material will name the product's brand name, state the approved indication, and include the line 'If you have not been prescribed this medicine, discuss it with your doctor.' We are encouraging appropriate medical consultation — not recommending off-label use — so there is no violation."
Verdict: BLACK. The explicit prohibition is that patient-facing disease education materials must not be interpreted as advertisements for a specific medicine. Naming the brand, stating the indication, and prompting patients who are not yet receiving the product to request it from their physician combines to produce exactly that: a patient-directed advertisement for a specific prescription drug. Under the PMD Act, advertising prescription drugs to the general public (including patients) is prohibited in principle; advertising is restricted to healthcare professionals. Good intentions — wanting patients to access treatment — do not alter the regulatory classification of the material.
Improper intent by implication — three scopes of "insinuating" without stating it
Disease education materials are nominally designed to help readers understand a condition, not to promote a product. Yet because a pharmaceutical company produces them, a single word slipped in at the end, the adjacency of a disease-mechanism section and a company product's mechanism-of-action diagram, or the arc of a patient-facing document from symptom suffering to treatment options can build the implicit argument: 'this disease makes life hard — this treatment solves it.'
Implication 1 — Local: carried in a single word or sentence
How it is built: "A healthcare professional disease education brochure ends with the sentence: 'For information on the characteristics of Product X, please contact your assigned MR.' No promotional language appears anywhere; this is solely a contact-information note."
Intent that can be read: Placing the product name immediately after a thorough disease explanation and directing the reader to the MR implies that Product X is the solution to the disease just described. The authority of the educational content becomes a springboard for the MR contact.
Verdict: Disease education materials exist to promote understanding of a condition. Adding a product-named contact prompt at the end converts the entire document into a funnel toward that product. The 'contact guide' format is an easy vehicle for rationalizing a product-name mention. When a product name appears at the close of a disease education document, the full document must be reviewed against the standards applied to promotional materials.
Implication 2 — Adjacent: read across neighboring clauses
How it is built: "In a healthcare professional disease education document, a page on treatment goals is followed directly by a mechanism-of-action diagram for the company's own Product Z (receptor-binding illustration). The diagram is captioned 'Mechanism of Action (Reference)'; no efficacy claims appear."
Intent that can be read: The page that defines 'what should be achieved therapeutically' is immediately followed by how Product Z works, implicitly completing the argument that Z achieves those treatment goals. The mechanism diagram makes no direct efficacy claim; the context makes it instead.
Verdict: Adjacent placement of a treatment-goal explanation and a product mechanism-of-action diagram transmits the message 'this product achieves the stated goal' without any explicit efficacy statement. When a company's own product's mechanism diagram is included in a disease education document, both the placement and the surrounding content context must be assessed in review — not only the caption text.
Implication 3 — Whole-context: arising from the document as a whole
How it is built: "A patient-facing disease education brochure is structured: (1) symptoms and their daily impact (emotionally resonant case vignettes), (2) treatment options (lifestyle modification and pharmacotherapy listed together; the pharmacotherapy entry names the company's own product as the sole concrete example), (3) a closing section encouraging the patient to consult their physician."
Intent that can be read: The document guides the patient from 'my symptoms are disrupting my life' to 'a specific named drug exists' to 'ask my doctor about it' — a sequence designed to generate prescription requests from patient to physician. It is patient-directed promotion wearing the label of disease education.
Verdict: A patient-facing disease education document structured around symptom suffering, a named company drug as the only specific pharmacotherapy option, and a physician-consultation close-out is assessed as a device for eliciting prescription requests. In patient-facing materials, promotion of a specific named drug is subject to regulation. The separation of disease education from promotion must be enforced at the document-design stage, not retrofitted after review.